Charles S. Fuchs - Net Worth and Insider Trading

Charles S. Fuchs Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Charles S. Fuchs owns 1 companies in total, including CytomX Therapeutics Inc (CTMX) .

Click here to see the complete history of Charles S. Fuchs’s form 4 insider trades.

Insider Ownership Summary of Charles S. Fuchs

Ticker	Comapny	Transaction Date	Type of Owner
CTMX	CytomX Therapeutics Inc	2018-06-13	director

Charles S. Fuchs Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Charles S. Fuchs Ownership Network

Ownership Network List of Charles S. Fuchs

No Data

Ownership Network Relation of Charles S. Fuchs

Charles S. Fuchs Owned Company Details

What does CytomX Therapeutics Inc do?

Who are the key executives at CytomX Therapeutics Inc?

Charles S. Fuchs is the director of CytomX Therapeutics Inc. Other key executives at CytomX Therapeutics Inc include SVP & Chief Scientific Officer Marcia Belvin , SVP & Finance and Accounting Christopher Ogden , and Chief Financial Officer Jeffrey B Landau .

CytomX Therapeutics Inc (CTMX) Insider Trades Summary

Over the past 18 months, Charles S. Fuchs made no insider transaction in CytomX Therapeutics Inc (CTMX). Other recent insider transactions involving CytomX Therapeutics Inc (CTMX) include a net sale of 62,273 shares made by Sean A. Mccarthy , a net sale of 25,172 shares made by Marcia Belvin , and a net sale of 19,012 shares made by Lloyd A Rowland .

In summary, during the past 3 months, insiders sold 28,425 shares of CytomX Therapeutics Inc (CTMX) in total and bought 0 shares, with a net sale of 28,425 shares. During the past 18 months, 132,341 shares of CytomX Therapeutics Inc (CTMX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 132,341 shares.

CytomX Therapeutics Inc (CTMX)'s detailed insider trading history can be found in Insider Trading Tracker table.

CytomX Therapeutics Inc Insider Transactions

No Available Data

Charles S. Fuchs Mailing Address

Above is the net worth, insider trading, and ownership report for Charles S. Fuchs. You might contact Charles S. Fuchs via mailing address: C/o Cytomx Therapeutics, Inc., 151 Oyster Point Blvd. Suite 400, South San Francisco Ca 94080.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.